(S022) Gender Differences in Time to Promotion and Scholarly Activity Among Academic Radiation Oncologists

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

Although the female RO full professors in our cohort were similar overall in terms of productivity and NIH funding to their male colleagues, they tended to have longer times to promotion earlier in their careers at lower academic ranks. Women may experience barriers to productivity early in their careers that may delay promotion.

Subha Perni, Reshma Jagsi, MD, DPhil, Mehee Choi, MD, Lynn D. Wilson, MD, Charles R. Thomas, Jr, MD, Clifton D. Fuller, MD, PhD, Emma B. Holliday, MD; Department of Radiation Oncology, Columbia University/New York Presbyterian Hospital; Department of Radiation Oncology, University of Michigan; Department of Radiation Oncology, Loyola University Chicago; Department of Therapeutic Radiology, Yale School of Medicine and Yale Cancer Center; Department of Radiation Medicine, Knight Cancer Institute, Oregon Health and Science University; Division of Radiation Oncology, UT MD Anderson Cancer Center

PURPOSE: To characterize the longitudinal relationship by gender between publication productivity, NIH funding, and academic promotion of current US academic professors of radiation oncology (RO).

METHODS: For full professors of RO departments, institutional websites were accessed to obtain training information and promotion dates. A commercial database (SCOPUS, Elsevier BV, Amsterdam, the Netherlands) was used to obtain productivity metrics, including publication number, citation number, and Hirsch index (h-index) at the time of each promotion, and National Institutes of Health (NIH) RePORTER (Research Portfolio Online Reporting Tools) was used to obtain NIH funding information. Pearson chi-square test and Wilcoxon rank-sum tests were used for comparisons of variables between men and women.

RESULTS: For 166 RO faculty full professors, there were no significant differences in degree, additional residency and fellowship training, year of RO residency graduation, number of institutions worked at as faculty, NIH funding status, number of publications, citations, h-indices, or m-indices. Women had a longer median time to promotion from assistant to associate professor when compared with men (8 yr, interquartile range [IQR]: 6–11 vs 6 yr, IQR: 5–8 yr; P = .049), as well as longer median time from associate to full professor (6 yr, IQR: 6–11 yr vs 5 yr, IQR: 4–6 yr; P = .004). However, there was no significant difference in time to appointment as chairperson. The h-index and NIH funding at promotion were not significantly different by gender at any of the promotion levels.

CONCLUSIONS: Although the female RO full professors in our cohort were similar overall in terms of productivity and NIH funding to their male colleagues, they tended to have longer times to promotion earlier in their careers at lower academic ranks. Women may experience barriers to productivity early in their careers that may delay promotion. 

Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Recent Videos
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content